Haleon Plc Stock Analysis
Recent assessments by Morgan Stanley reveal a cautiously optimistic outlook for Haleon Plc (NYSE:HLN). The investment firm has slightly reduced its price target for the company's shares from $10.95 to $10.65. This revision, however, has not affected their Overweight rating on the stock, indicating confidence in Haleon’s future performance. The changes come as analysts prepare for the anticipated quarterly results set to unveil later in the year.
Growth Forecasts and Expectations
Despite the modest adjustment, Morgan Stanley has held steady on its year-over-year organic growth estimate for fiscal year 2024 at 5.0%, which is slightly ahead of the consensus projection of 4.9%. Nonetheless, the firm has recalibrated its expectations for third-quarter growth, now estimating growth at 6.3%, down from a previous forecast of 7.5%. This downward adjustment reflects a projected tougher environment for the vitamin, mineral, and supplement (VMS) segment in the U.S., prompted by current market dynamics and past performance benchmarks.
Impact of Market Changes
In addition to the growth adjustments, the anticipated margins for Haleon have been slightly lowered from 22.9% to 22.6%. This revision considers the consequences of the recent divestment of the Nicotine Replacement Therapy (NRT) business and shifts in foreign exchange rates. Despite these changes, Morgan Stanley still envisions a robust 9% organic EBIT growth trajectory for the full fiscal year.
EPS Forecast Adjustments
The firm has also lowered the earnings per share (EPS) estimates for fiscal years 2025 and 2026 by less than 1%. This slight decline comes after reviewing the implications of Haleon increasing its stake in its joint venture based in China, prompting adjustments in the price target alongside updates in the USD/GBP exchange rates.
Corporate Developments at Haleon
Recently, Haleon has been active in the capital markets, notably completing a £230 million off-market share repurchase from Pfizer Inc. (NYSE:PFE). Furthermore, the consumer healthcare leader finalized the sale of its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for a deal potentially reaching £500 million. Additionally, Haleon has increased its stake in the Tianjin TSKF Pharmaceutical Co. Ltd joint venture to an impressive 88%.
Analyst Perspectives
Several analysts have recently modified their outlook on Haleon. Morgan Stanley and BofA Securities have uplifted their price targets, while Goldman Sachs has shifted its rating from "Buy" to "Neutral." Meanwhile, Berenberg has begun covering the stock, issuing a favorable "Buy" rating in their analysis. The company also made headlines with the launch of Eroxon®, the inaugural FDA-cleared over-the-counter gel in the U.S. for treating erectile dysfunction.
Board Changes and Governance
In terms of corporate governance, recent board changes included the resignation of Alan Stewart. The company has also smoothly executed a share buyback program to bolster its employee share schemes for the year 2025.
Key Financial Insights
Exploring further insights, current data highlights Haleon’s market capitalization at around $44.76 billion, illustrating its strong foothold in the healthcare sector. The company showcases robust gross profit margins, currently reported at 62.54% for the last twelve months as of Q2 2024, complementing Morgan Stanley's encouraging outlook on organic EBIT growth.
Competitiveness and Market Position
InvestingPro insights reveal Haleon is operating at a moderate debt level, signifying a healthy financial structure that supports profitability in the face of market challenges. However, its revenue growth trajectory remains somewhat flat, with a recent slight decrease of 1.31%. This stagnation can be attributed to difficulties within the VMS segment. Conversely, a minor quarterly revenue growth of 0.84% in Q2 2024 suggests a possible reversal in fortunes ahead.
Frequently Asked Questions
What is Haleon Plc’s current stock price target?
Morgan Stanley recently adjusted Haleon's price target to $10.65.
What growth is expected for Haleon in fiscal year 2024?
Haleon is projected to achieve a 5.0% organic growth in fiscal year 2024.
What recent corporate actions has Haleon taken?
Haleon completed a significant share repurchase and divested its nicotine replacement therapy business.
How does Haleon's market capitalization reflect its position?
Haleon has a market capitalization of approximately $44.76 billion, indicating its strength in consumer healthcare.
Which notable product did Haleon launch recently?
Haleon launched Eroxon®, the first FDA-cleared over-the-counter gel for erectile dysfunction in the U.S.
